ARTICLES BY THIS AUTHOR
- 10/8/2019
California law enables pharmacists to dispense PrEP and PEP without a prescription
SB 159 authorizes pharmacists to prescribe PrEP and PEP to patient without a physician prescription and prohibits insurance companies from requiring patients to obtain prior authorization before using their insurance benefits to obtain PrEP or PEP. - 10/7/2019
Fresenius Kabi introduces generic Faslodex
Fresenius Kabi developed its fulvestrant injection prefilled syringe to be stable at room temperature, so that it doesn't require refrigeration. - 10/7/2019
Galderma gets FDA blessing for Aklief
Galderma's Aklief (trifarotene cream) is the first new retinoid molecule to receive FDA approval for the treatment of acne in more than 20 years - 10/7/2019
AstraZeneca gets FDA clearance for Fasenra
AstraZeneca's Fasenra is the only respiratory biologic that offers the choice of administration at home or in a doctor’s office with eight-week maintenance dosing, the company said. - 10/7/2019
Pfenex gets FDA nod for potential Forteo generic
Forteo had a global market value of $1.6 billion in 2018. - 10/4/2019
AmerisourceBergen selected by Karyopharm to support Xpovio
AmerisourceBergen has been chosen by Karyopharm to introduce a new treatment for patients with relapsed or refractory multiple myeloma. - 10/4/2019
NACDS 21st annual Foundation Dinner to feature entertainer Jim Gaffigan
Grammy award-nominated entertainer Jim Gaffigan will headline NACDS Foundation dinner, which is dedicated to improving patient outcomes and public health. - 10/4/2019
Schnucks set to end tobacco sales in January
Beginning Jan. 1, 2020 Schnuck Markets will end all tobacco product sales, and starting Oct. 15 it will offer double Schnucks Rewards points on all OTC smoking cessation products. - 10/4/2019
FDA approves Gilead’s Descovy as PrEP
Descovy is the second FDA approved to prevent HIV infection. - 10/4/2019
FDA approves new indication for AbbVie’s Mavyret
Mavyret is now the first eight-week treatment approved for all treatment-naïve adult and certain pediatric patients with HCV genotypes 1-6 both without cirrhosis and with compensated cirrhosis.